Quince Therapeutics (NASDAQ:QNCX - Get Free Report) is anticipated to post its Q4 2024 quarterly earnings results after the market closes on Monday, March 24th. Analysts expect Quince Therapeutics to post earnings of ($0.18) per share for the quarter.
Quince Therapeutics Price Performance
Shares of QNCX stock traded up $0.02 during mid-day trading on Monday, hitting $1.40. The company had a trading volume of 265,370 shares, compared to its average volume of 243,852. The company has a market capitalization of $61.60 million, a P/E ratio of -1.13 and a beta of 0.71. The stock's 50 day moving average price is $1.49 and its 200-day moving average price is $1.44. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. D. Boral Capital restated a "buy" rating and set a $12.00 price objective on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Brookline Capital Management started coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a "buy" rating and a $9.00 price target for the company. Finally, Oppenheimer began coverage on Quince Therapeutics in a report on Monday. They set an "outperform" rating and a $10.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Quince Therapeutics has a consensus rating of "Buy" and a consensus price target of $9.60.
View Our Latest Analysis on Quince Therapeutics
Quince Therapeutics Company Profile
(
Get Free Report)
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Featured Articles
Before you consider Quince Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quince Therapeutics wasn't on the list.
While Quince Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
